{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:12:22Z","timestamp":1791623542759,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The study was funded by Teva Ratiopharm, Merckle GmbH."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23258-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:40:50Z","timestamp":1762972850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An open-label, randomized study comparing lipegfilgrastim with filgrastim in pediatric patients receiving chemotherapy for Ewing sarcoma or rhabdomyosarcoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5797-1234","authenticated-orcid":false,"given":"Margarita B.","family":"Belogurova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lammerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Barkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayoung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"23258_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMc2102423","volume":"384","author":"JA Ludwig","year":"2021","unstructured":"Ludwig, J. A., Meyers, P. A. & Dirksen, U. Ewing\u2019s sarcoma. N Engl. J. Med. 384, 1476. https:\/\/doi.org\/10.1056\/NEJMc2102423 (2021).","journal-title":"N Engl. J. Med."},{"issue":"Suppl 2","key":"23258_CR2","doi-asserted-by":"publisher","first-page":"e28254","DOI":"10.1002\/pbc.28254","volume":"68","author":"RL Yechieli","year":"2021","unstructured":"Yechieli, R. L. et al. Rhabdomyosarcoma. Pediatr. Blood Cancer. 68 (Suppl 2), e28254. https:\/\/doi.org\/10.1002\/pbc.28254 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"23258_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/1120009x.1990.11738996","volume":"2","author":"G Bacci","year":"1990","unstructured":"Bacci, G. et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J. Chemother. 2, 127\u2013135. https:\/\/doi.org\/10.1080\/1120009x.1990.11738996 (1990).","journal-title":"J. Chemother."},{"key":"23258_CR4","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1200\/jco.2000.18.12.2427","volume":"18","author":"KS Baker","year":"2000","unstructured":"Baker, K. S. et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 18, 2427\u20132434. https:\/\/doi.org\/10.1200\/jco.2000.18.12.2427 (2000).","journal-title":"J. Clin. Oncol."},{"key":"23258_CR5","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/jnci\/83.20.1460","volume":"83","author":"MA Smith","year":"1991","unstructured":"Smith, M. A., Ungerleider, R. S., Horowitz, M. E. & Simon, R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing\u2019s sarcoma. J. Natl. Cancer Inst. 83, 1460\u20131470. https:\/\/doi.org\/10.1093\/jnci\/83.20.1460 (1991).","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl 1","key":"23258_CR6","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jinf.2015.04.026","volume":"71","author":"CD Barton","year":"2015","unstructured":"Barton, C. D., Waugh, L. K., Nielsen, M. J. & Paulus, S. Febrile neutropenia in children treated for malignancy. J. Infect. 71 (Suppl 1), S27\u201335. https:\/\/doi.org\/10.1016\/j.jinf.2015.04.026 (2015).","journal-title":"J. Infect."},{"key":"23258_CR7","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky, J. et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann. Oncol. 27, v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325 (2016).","journal-title":"Ann. Oncol."},{"key":"23258_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10147-022-02282-x","volume":"28","author":"S Osone","year":"2023","unstructured":"Osone, S. et al. Current methods of preventing infectious disease and managing febrile neutropenia in childhood cancer patients: a nationwide survey in Japan. Int. J. Clin. Oncol. 28, 331\u2013340. https:\/\/doi.org\/10.1007\/s10147-022-02282-x (2023).","journal-title":"Int. J. Clin. Oncol."},{"key":"23258_CR9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1001\/jamaoncol.2017.1114","volume":"3","author":"K Patel","year":"2017","unstructured":"Patel, K., & West, H. J. Febrile Neutropenia JAMA Oncol. 3, 1751 https:\/\/doi.org\/10.1001\/jamaoncol.2017.1114 (2017).","journal-title":"JAMA Oncol."},{"key":"23258_CR10","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1200\/jco.2016.71.7017","volume":"35","author":"T Lehrnbecher","year":"2017","unstructured":"Lehrnbecher, T. et al. Guideline for the Management of Fever and Neutropenia in Children with Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J. Clin. Oncol. 35, 2082\u20132094. https:\/\/doi.org\/10.1200\/jco.2016.71.7017 (2017).","journal-title":"J. Clin. Oncol."},{"key":"23258_CR11","unstructured":"European Medicines Agency. Nivestim [filgrastim] summary of product characteristics. (2015). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nivestim-epar-product-information_en.pdf"},{"key":"23258_CR12","unstructured":"European Medicines Agency. Neulasta [pegfilgrastim] summary of product characteristics. (2007). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/neulasta-epar-product-information_en.pdf"},{"key":"23258_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/CAD.0b013e328011a532","volume":"18","author":"N Andr\u00e9","year":"2007","unstructured":"Andr\u00e9, N. et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs. 18, 277\u2013281. https:\/\/doi.org\/10.1097\/CAD.0b013e328011a532 (2007).","journal-title":"Anticancer Drugs"},{"key":"23258_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/pbc.22086","volume":"53","author":"SC Borinstein","year":"2009","unstructured":"Borinstein, S. C., Pollard, J., Winter, L. & Hawkins, D. S. Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr. Blood Cancer. 53, 375\u2013378. https:\/\/doi.org\/10.1002\/pbc.22086 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"23258_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/bmt.2008.206","volume":"42","author":"S Dallorso","year":"2008","unstructured":"Dallorso, S. et al. Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy. Bone Marrow Transplant\u00a042, 507\u2013513. https:\/\/doi.org\/10.1038\/bmt.2008.206 (2008).","journal-title":"Bone Marrow Transplant"},{"key":"23258_CR16","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1158\/1078-0432.Ccr-09-0761","volume":"15","author":"E Fox","year":"2009","unstructured":"Fox, E. et al. Randomized trial and Pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin. Cancer Res. 15, 7361\u20137367. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0761 (2009).","journal-title":"Clin. Cancer Res."},{"key":"23258_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/jco.2009.24.8872","volume":"28","author":"SL Spunt","year":"2010","unstructured":"Spunt, S. L. et al. Phase II, randomized, open-label study of pegfilgrastim-supported VDC\/IE chemotherapy in pediatric sarcoma patients. J. Clin. Oncol. 28, 1329\u20131336. https:\/\/doi.org\/10.1200\/jco.2009.24.8872 (2010).","journal-title":"J. Clin. Oncol."},{"key":"23258_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/01.mph.0000188631.41510.23","volume":"27","author":"EM te Poele","year":"2005","unstructured":"te Poele, E. M. et al. Pegfilgrastim in pediatric cancer patients. J. Pediatr. Hematol. Oncol. 27, 627\u2013629. https:\/\/doi.org\/10.1097\/01.mph.0000188631.41510.23 (2005).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"23258_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/01.mph.0000175711.73039.63","volume":"27","author":"G Wendelin","year":"2005","unstructured":"Wendelin, G., Lackner, H., Schwinger, W., Sovinz, P. & Urban, C. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J. Pediatr. Hematol. Oncol. 27, 449\u2013451. https:\/\/doi.org\/10.1097\/01.mph.0000175711.73039.63 (2005).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"23258_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17512433.2022.2110066","volume":"15","author":"H Kim","year":"2022","unstructured":"Kim, H. & Mousa, S. A. Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children. Expert Rev. Clin. Pharmacol. 15, 977\u2013986. https:\/\/doi.org\/10.1080\/17512433.2022.2110066 (2022).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"23258_CR21","unstructured":"Food and Drug Administration. Neulasta [pegfilgrastim] Prescribing information. (2019). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125031s198lbl.pdf"},{"key":"23258_CR22","unstructured":"European Medicines Agency. EPAR \u2013 public assessment report: Lonquex (lipegfilgrastim). (2013). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lonquex-epar-public-assessment-report_en.pdf"},{"key":"23258_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"13","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko, I., Gladkov, O. A., Elsaesser, R., Buchner, A. & Bias, P. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer. 13, 386. https:\/\/doi.org\/10.1186\/1471-2407-13-386 (2013).","journal-title":"BMC Cancer"},{"key":"23258_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40064-015-1067-7","volume":"4","author":"C Volovat","year":"2015","unstructured":"Volovat, C. et al. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. Springerplus 4, 316. https:\/\/doi.org\/10.1186\/s40064-015-1067-7 (2015).","journal-title":"Springerplus"},{"key":"23258_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-016-3216-2","volume":"79","author":"MB Belogurova","year":"2017","unstructured":"Belogurova, M. B. et al. A Pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma. Cancer Chemother. Pharmacol. 79, 155\u2013164. https:\/\/doi.org\/10.1007\/s00280-016-3216-2 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"23258_CR26","unstructured":"European Medicines Agency. Summary of opinion (post authorisation) Lonquex (lipegfilgrastim). (2022). https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-lonquex-ii-58-g_en.pdf"},{"key":"23258_CR27","unstructured":"European Medicines Agency. Lonquex [lipegfilgrastim] summary of product characteristics. (2023). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lonquex-epar-product-information_en.pdf"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23258-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:40:52Z","timestamp":1762972852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23258"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23258-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Margarita B. Belogurova reports grants from TEVA Pharmaceuticals during the conduct of the study. Andreas Lammerich reports employment by Teva ratiopharm during the conduct of the study. Hadas Barkay reports employment by Teva Pharmaceutical Industries during the conduct of the study. Dayoung Seo reports employment by Teva-Handok since 2021. Anton Buchner reports employment by Teva ratiopharm and received stock options during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39696"}}